Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Caladrius Bio (CLBS)

Caladrius Bio (CLBS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Caladrius Bio 110 ALLEN ROAD 2ND FLOOR BASKING RIDGE NJ 07920 USA

P: 908-842-0100

Description:

Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York.

Key Statistics

Overview:

Market Capitalization, $K 72,016
Shares Outstanding, K 59,517
Annual Sales, $ 0 K
Annual Net Income, $ -8,150 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -5,680 K
60-Month Beta 1.04
% of Insider Shareholders 2.20%
% of Institutional Shareholders 10.53%
Float, K 58,208
% Float 97.80%

Growth:

1-Year Return -33.71%
3-Year Return -77.38%
5-Year Return -74.03%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 88.28%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 08/05/21
Earnings Per Share ttm -0.86
EPS Growth vs. Prev Qtr 47.37%
EPS Growth vs. Prev Year 69.70%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 07/28/16

CLBS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -2.66
Price/Earnings to Growth N/A
Return-on-Equity % -34.46%
Return-on-Assets % -32.53%
Profit Margin % 0.00
Net Margin % N/A
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.72
Book Value/Share 1.76
Interest Coverage 0.00
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar